<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">646</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2022-21-4-152-157</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Spindle cell neoplasm harboring MAPK signaling pathway gene translocation from the spectrum of <italic>NTRK</italic>-rearranged spindle cell tumor</article-title><trans-title-group xml:lang="ru"><trans-title>Веретеноклеточная опухоль с транслокацией гена сигнального пути MAPK из спектра <italic>NTRK</italic>-перестроенной веретеноклеточной неоплазии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9496-3136</contrib-id><name-alternatives><name xml:lang="en"><surname>Tarakanova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Тараканова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Alexandra V. Tarakanova</bold>, a resident in Anatomical Pathology</p><p><italic>117997, Moscow, Samory Mashela St., 1</italic></p></bio><bio xml:lang="ru"><p><bold>Тараканова Александра Васильевна</bold>, ординатор по специальности «патологическая анатомия»</p><p><italic>117997, Москва, ул. Саморы Машела, 1</italic></p></bio><email>sequaciou@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5354-7067</contrib-id><name-alternatives><name xml:lang="en"><surname>Sharlay</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Шарлай</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8580-3499</contrib-id><name-alternatives><name xml:lang="en"><surname>Panferova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Панферова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8578-6572</contrib-id><name-alternatives><name xml:lang="en"><surname>Sidorov</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Сидоров</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7732-8184</contrib-id><name-alternatives><name xml:lang="en"><surname>Konovalov</surname><given-names>D. M.</given-names></name><name xml:lang="ru"><surname>Коновалов</surname><given-names>Д. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-26" publication-format="electronic"><day>26</day><month>12</month><year>2022</year></pub-date><volume>21</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>152</fpage><lpage>157</lpage><history><date date-type="received" iso-8601-date="2022-09-01"><day>01</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-09-21"><day>21</day><month>09</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/646">https://hemoncim.com/jour/article/view/646</self-uri><abstract xml:lang="en"><p>Definition of novel nosological entities based on specific genetic aberrations is becoming more common tendency regarding neoplasms of all sites. Diagnostic approach to such entity represents an urgent issue of modern oncopathology due to the importance of further accurate genetic examination. NTRK-rearranged spindle cell neoplasm is one of such categories and includes a broad spectrum of entities with similar morphology and immunophenotype. Due to the recognition of a variety of related genes and their anomalies, as well as overlapping pathomorphological criteria, the diagnosis NTRK-rearranged spindle cell neoplasia may be an outstanding issue. Based on the clinical case, a possible algorithm of diagnostic approach to this entity is suggested in this article. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.</p></abstract><trans-abstract xml:lang="ru"><p>Тенденция к выделению нозологических единиц на основании специфических генетических аномалий с каждым годом становится все более выраженной в отношении новообразований всех локализаций. Разработка подхода к такому диагнозу для дальнейшей корректной маршрутизации пациента на генетическое исследование является актуальным вопросом современной онкопатологии. Выделенная классификацией Всемирной организации здравоохранения 2020 г. NTRK-перестроенная веретеноклеточная неоплазия является одной из таких нозологических форм и представляет собой целый спектр новообразований со сходными морфологией и иммунофенотипом. В связи с существованием множества заинтересованных генов и их аномалий, а также перекрывающимися гистологическими критериями диагностика новообразований группы NTRK-перестроенной веретеноклеточной неоплазии может представлять трудности. В статье на конкретном клиническом примере рассмотрен возможный алгоритм диагностического поиска в отношении этой нозологии. Родители пациентки дали согласие на использование информации, в том числе фотографий ребенка, в научных исследованиях и публикациях.</p></trans-abstract><kwd-group xml:lang="en"><kwd>NTRK-rearranged spindle cell tumor</kwd><kwd>infantile fibrosarcoma</kwd><kwd>NTRK</kwd><kwd>MAPK</kwd><kwd>BRAF</kwd><kwd>MTAP</kwd><kwd>lipofibromatosis</kwd><kwd>malignant peripheral nerve sheaths tumor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>NTRK-перестроенная веретеноклеточная опухоль</kwd><kwd>инфантильная фибросаркома</kwd><kwd>NTRK</kwd><kwd>MAPK</kwd><kwd>BRAF</kwd><kwd>MTAP</kwd><kwd>липофиброматоз</kwd><kwd>злокачественная опухоль из оболочек периферических нервов</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Davis J.L., Lockwood С.М., Stohr В., Boecking С., Al-Ibraheemi А., DuBois S.G., et al. Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. Am J Surg Pathol 2019; 43 (4): 435–45. DOI:10.1097/PAS.0000000000001203</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Davis J.L., Al-Ibraheemi A., Rudzinski E.R., Surrey L.F. Mesenchymal neoplasms with NTRK and other kinase gene alterations. Histopathology 2022; 80 (1): 4–18. DOI:10.1111/his.14443</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Antonescu C.R. Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria. Genes Chromosomes Cancer 2020; 59 (8): 437–44. DOI:10.1002/gcc.22846</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Suurmeijer A.J.H., Dickson B.C., Swanson D., Zhang L., Sung Y.S., Cotzia P., et al. A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 2018; 57: 611–21. DOI:10.1002/gcc.22671</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (France): International Agency for Research on Cancer; 2020.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Penning A.J., Al-Ibraheemi A., Michal M., Larsen В.Т., Cho S.-J., Lockwood С.М., et al. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma. Mod Pathol 2021; 34: 1530–40. DOI:10.1038/s41379-021-00806-w</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Antonescu C.R., Dickson B.C., Swanson D., Zhang L., Sung Y.S., Kao Y.C., et al. Spindle cell tumors with RET gene fusions exhibit a morphologic spectrum akin to tumors with NTRK gene fusions. Am J Surg Pathol 2019; 43: 1384–91. DOI:10.1097/PAS.0000000000001297</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Wegert J., Vokuhl C., Collord G., Velasco-Herrera M.D.C., Farndon S.J., Guzzo C., et al. Recurrent intragenic rearrangement of EGFR and BRAF in soft tissue tumors of infants. Nat Commun 2018; 9: 2378. DOI:10.1038/s41467-018-04650-6</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kao Y.C., Fletcher C.D.M., Alaggio R., Wexler R., Zhang L., Sung Y.S., et al. Recurrent BRAF gene fusions in a subset of pediatric spindle cell sarcomas–expanding the genetic spectrum of tumors with overlapping features with infantile fibrosarcoma. Am J Surg Pathol 2018; 42: 28–38. DOI:10.1097/PAS.0000000000000938</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hechtman J.F. NTRK insights: best practices for pathologists. Mod Pathol 2022; 35 (3): 298–305. DOI:10.1038/s41379-021-00913-8</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Jain P., Surrey L.F., Straka J., Russo P., Womer R., Li M.M., еt al. BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. Pediatr Blood Cancer 2021; 68 (6). DOI:10.1002/pbc.28933.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Leiner J., Le Loarer F. The current landscape of rhabdomyosarcomas: an update. Virchows Arch 2020; 476 (1): 97–108. DOI:10.1007/s00428-019-02676-9</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Stacchiotti S., Van Tine B.A. Synovial Sarcoma: Current Concepts and Future Perspectives. J Clin Oncol 2018; 36 (2): 180–7. DOI:10.1200/JCO.2017.75.1941</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Huang S.C., Huang H.Y. Solitary fibrous tumor: An evolving and unifying entity with unsettled issues. Histol Histopathol 2019; 34 (4): 313–34. DOI:10.14670/HH-18-064</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ji Y., Chen S., Yang K., Xia C., Li L. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis 2020; 15 (1): 39. DOI:10.1186/s13023-020-1320-1</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Yoshino T. JSCO-ESMO-ASCO-JSMOTOS: international expert consensus recommendations for tumor-agnostic treatments in patients with solid tumors with microsatellite instability or NTRK fusions. Ann Oncol 2020; 31 (7): 861–72. DOI:10.1016/j.annonc.2020.03.299</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Иванов Н.С., Панферова А.В., Коновалов Д.М., Телешова М.В., Большаков Н.А., Шаманская Т.В. и др. Врожденная инфантильная фибросаркома с неканоническим химерным транскриптом TPM3-NTRK1: описание клинического случая и обзор литературы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022; 21 (1): 110–20. DOI:10.24287/1726-1708-2022-21-1-110-120</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Seto K., Haneda M., Masago K., Fujita S., Kato S., Sasaki E., еt al. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF. Pathol Int 2020; 70 (5): 253–61. DOI:10.1111/pin.12903</mixed-citation></ref></ref-list></back></article>
